TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.
Brief Summary: This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.


Options:
A: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide - Exenatide - Placebo | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: Exenatide - Placebo - Exenatide | Arm Label: Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo - Exenatide - Exenatide | Intervention Type: DRUG; Name: Exenatide - Exenatide - Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Exenatide - Placebo - Exenatide; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo - Exenatide - Exenatide; Assigned to Arm(s): Sequence 3
B: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: exenatide, long acting release | Arm Label: Exenatide Twice Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: exenatide, long acting release; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide Twice Daily
C: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proactive Communication Strategy for Family Members of Patients Dying in the ICU: A Multicenter Randomized Controlled Trial
Brief Summary: Decisions to limit life sustaining treatments are made for most patients dying in the ICU, usually with input from the family. The well-being of the family may be jeopardized by involvement in the decision-making process and bereavement. We evaluated the ability of a proactive communication strategy (family conference and providing family members with a bereavement information leaflet) designed to improve family well-being.


Options:
A: Arm Label: Supportive Information Team Group; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive Information Team Group | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supportive Information Team Group; Assigned to Arm(s): Supportive Information Team Group
B: Arm Label: Intensive Communication; Type: EXPERIMENTAL; Interventions: Other: Intensive Communication System | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intensive Communication System; Assigned to Arm(s): Intensive Communication
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Structured information | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Unspecific conversation | Intervention Type: BEHAVIORAL; Name: Structured information; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Unspecific conversation; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: family conference with bereavement information leaflet; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proactive Communication Strategy for Family Members of Patients Dying in the ICU: A Multicenter Randomized Controlled Trial
Brief Summary: Decisions to limit life sustaining treatments are made for most patients dying in the ICU, usually with input from the family. The well-being of the family may be jeopardized by involvement in the decision-making process and bereavement. We evaluated the ability of a proactive communication strategy (family conference and providing family members with a bereavement information leaflet) designed to improve family well-being.


Options:
A: Arm Label: Clinicians with MI coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Wait-list control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list control | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Clinicians with MI coaching | Intervention Type: BEHAVIORAL; Name: Wait-list control; Assigned to Arm(s): Wait-list control
B: Arm Label: ICU Usual Care Control; Type: ACTIVE_COMPARATOR; Interventions: Other: ICU Usual Care Control | Arm Label: The PARTNER Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The PARTNER Intervention | Intervention Type: BEHAVIORAL; Name: The PARTNER Intervention; Assigned to Arm(s): The PARTNER Intervention | Intervention Type: OTHER; Name: ICU Usual Care Control; Assigned to Arm(s): ICU Usual Care Control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Decision support skills building Intervention | Intervention Type: BEHAVIORAL; Name: Decision support skills building Intervention; Assigned to Arm(s): 1
D: Intervention Type: PROCEDURE; Name: family conference with bereavement information leaflet; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement.
Brief Summary: The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate
D: Intervention Type: PROCEDURE; Name: Bilateral ultrasound examination 7+/- 2 after surgery; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)
Brief Summary: This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Arm Label: Balovaptan; Type: EXPERIMENTAL; Interventions: Drug: Balovaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Balovaptan; Assigned to Arm(s): Balovaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)
Brief Summary: This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
C: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproate, Drug: Risperidone, Drug: Stimulant medication, Behavioral: Behavioral family counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Valproate, Drug: Risperidone, Drug: Stimulant medication, Behavioral: Behavioral family counseling | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Stimulant medication, Behavioral: Behavioral family counseling | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Stimulant medication; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BEHAVIORAL; Name: Behavioral family counseling; Assigned to Arm(s): 1, 2, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)
Brief Summary: This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
D: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis
Brief Summary: Protocol Summary

Title: Evaluation of safety and efficacy of two different once daily anti-retroviral treatment regimens along with anti-tuberculosis treatment in patients with HIV-1 and tuberculosis - Randomized Controlled Clinical Trial

Phase: Phase III trial

Population: 180 HIV-1 positive patients with tuberculosis

Number of Sites: Four.

1. Tuberculosis Research Centre, Chennai
2. Government Medical College, Vellore
3. Government Hospital of Thoracic Medicine, Tambaram
4. Government Rajaji Hospital, Madurai

Study Duration: 26 months including 24 months of ART.

Study Objectives:

Primary Objective To compare the efficacy and safety of two different once-daily anti-retroviral treatment regimens (along with standard anti-tuberculosis treatment) in patients with HIV-1 and tuberculosis, by using virologic end points.

Secondary Objective To compare the efficacy of antiretroviral treatment given under partial supervision with unsupervised treatment (once a month supply).


Options:
A: Arm Label: Efavirenz; Type: EXPERIMENTAL; Interventions: Drug: efavirenz | Arm Label: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: nevirapine | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Efavirenz | Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): Nevirapine
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Didanosine, Lamivudine, Nevirapine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Didanosine, Lamivudine, Efavirenz | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Efavirenz; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Intervention Type: DRUG; Name: Nevirapine based therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Efavirenz based therapy; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z); Assigned to Arm(s): 1, 2
D: Arm Label: Intervention 2: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: Intervention 2: Efavirenz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Intervention 2: Nevirapine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Intervention 2: Efavirenz

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
D: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Weekly Motivational Emails | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Weekly Motivational Emails | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Weekly Motivational Emails; Assigned to Arm(s): Bupropion, Varenicline
B: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
C: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6

Answer: D